Professor John McMurray, Professor of Cardiology (Cardiology & Metabolic Health), School of Cardiovascular and Metabolic Health
Professor Richard Hobbs, Mercian Professor of Primary Care, University of Oxford

Referneces

1. Piccirillo F, Liporace P et al. Effects of finerenone on cardiovascular and chronic kidney diseases: a new weapon against cardiorenal morbidity and mortality‑a comprehensive review. J Cardiovasc Dev Dis 2023;10:236.
2. Kolkhof P, Jaisser F et al. Steroidal and novel non‑steroidal mineralocorticoid receptor antagonists in heart failure and cardiorenal diseases: comparison at bench and bedside. In Bauersachs J et al (eds): Heart failure. Springer International Publishing, Cham, Switzerland, 2017:271‑305.
3. Spironolactone Summary of Product Characteristics. Available at: medicines.org.uk.
4. Eplerenone Summary of Product Characteristics. Available at: medicines.org.uk.

• Early detection and accurate diagnosis are essential for optimising clinical management and improving outcomes in patients with amyloidosis
• The National Amyloidosis Centre has a range of advanced diagnostic techniques to confirm the presence of amyloidosis in a person
• Investigations may include SAP scintigraphy, cardiac MRI scans, DPD scans and genetic testing
• Accurate subtyping enables tailored therapeutic strategies, which are key to effective disease management

Speakers

Angelique Smit, Lead Clinical and Research Nurse
Darren Foard, Lead AL Amyloidosis Clinical Nurse Specialist
David Hutt, Lead Nuclear Medicine Technologist
Dr Tamer Rezk, Consultant Nephrologist
Dr Ana Martinez Naharro, Consultant Cardiologist
Dr Dorota Rowczenio, Head of Genetic Service
Emily Dixon, Principal Genetic Counsellor
Professor Philip Hawkins, Consultant Physician; Clinical Director; Founder of NAC

• Early detection and diagnosis are key for improving outcomes in people with amyloidosis
• 3 major types of amyloidosis: TTR amyloidosis, AL amyloidosis and AA amyloidosis
• The NAC processes over 2500 cases of amyloidosis per year and offers a holistic approach to managing amyloidosis including genetic counselling

Speakers

Angelique Smit, Lead Clinical and Research Nurse
Professor Philip Hawkins, Consultant Physician; Clinical Director; Founder of NAC
Professor Ashu Wechalekar, Laboratory Director and Consultant Haematologist
Janet Gilbertson, Head of Histology; Proteomic Service and Laboratory Manager
Dr Yousuf Razvi, Clinical Research Fellow
Professor Marianna Fontana, Deputy Clinical and Research Lead
Dr Carol Whelan, Consultant Cardiologist
Professor Julian Gillmore, NAC Research Lead
Emily Dixon, Principal Genetic Counsellor
Dr Tamer Rezk, Consultant Nephrologist
Christine Chiti, Clinical TTR Nurse Specialist

1. Bennani SY et al. Int J Cardiovasc Imaging 2016;32:1403–13

Professor Marianna Fontana, Professor of Cardiology and Honorary Consultant Cardiologist at the National Amyloidosis Centre, University College London

For more expert-led non-promotional content on heart failure, cardiac amyloidosis and ATTR-CM, please visit the Pfizer Medical website. Clicking this link will redirect you to the Pfizer Medical website, a non-promotional website developed and funded by Pfizer Ltd. for UK healthcare professionals.

Abbreviation:
ATTR-CM: Transthyretin amyloid cardiomyopathy.

PP-UNP-GBR-14079 | March 2026

Dr William E Moody, Consultant Cardiologist, Queen Elizabeth Hospital, Birmingham

For more expert-led non-promotional content on heart failure, cardiac amyloidosis and transthyretin amyloid cardiomyopathy, please visit the Pfizer Medical website. Clicking this link will redirect you to the Pfizer Medical website, a non-promotional website developed and funded by Pfizer Ltd. for UK healthcare professionals.

Reference

Moody, William E et al. “British Society of Echocardiography guideline for the transthoracic echocardiographic assessment of cardiac amyloidosis.” Echo research and practice vol. 10,1 13. 31 Aug. 2023, doi:10.1186/s44156-023-00028-7

Abbreviations:
ECHO: echocardiography; TTE: transthoracic echocardiography.

PP-UNP-GBR-14075 | March 2026

Watch a full-length on-demand video and explore other educational materials, designed to further your understanding of avoiding treatment limbo and alternative approaches to managing dyslipidaemia.

Click here to access prescribing information and adverse event reporting information for Praluent® (alirocumab).